Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

17 projects found matching your search criteria :

  1. DNA repair pathways contributing to resistance to photodynamic therapy and as possible theraupeutic targets

    Call: OPUS 8 , Panel: NZ5

    Principal investigator: dr hab. Elżbieta Speina

    Instytut Biochemii i Biofizyki PAN

  2. Efficiency of photodynamic reaction enhanced electroporation in human cancer cells sensitive and resistant to chemothera...

    Call: SONATA 1 , Panel: NZ4

    Principal investigator: dr Julita Kulbacka

    Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

  3. Role of the PARP1/HPF1 complex in the conferring of resistance to doxorubicin in triple negative breast cancer

    Call: PRELUDIUM 21 , Panel: NZ5

    Principal investigator: Magdalena Strachowska

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  4. New strategy for overcoming resistance to chemotherapy of ovarian cancer by modulation of the canonical and non-canonica...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr hab. Radosław Januchowski

    Uniwersytet Zielonogórski, Collegium Medicum

  5. Inhibiting the Mitochondrial Intermembrane Space Assembly pathway as a newapproach to prevent metabolic reprogramming of...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr hab. Carlo Vascotto

    Instytut Hematologii i Transfuzjologii

  6. Analysis of semaphorin 3 (SEMA3), protocadherin 9 (PCDH9) and S 100 calcium binding proteinA3 (S100A3) expression in pro...

    Call: OPUS 21 , Panel: NZ5

    Principal investigator: dr hab. Radosław Januchowski

    Uniwersytet Zielonogórski, Collegium Medicum

  7. Changes in lipid metabolism of resistant to BRAF/MEK inhibitors human melanoma cells associated with the presence of adi...

    Call: SONATA 16 , Panel: NZ5

    Principal investigator: dr Aleksandra Simiczyjew

    Uniwersytet Wrocławski, Wydział Biotechnologii

  8. Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.

    Call: PRELUDIUM 19 , Panel: NZ7

    Principal investigator: Marek Jamrozik

    Uniwersytet Jagielloński, Collegium Medicum

  9. Concept of the universal antibody targeting tumor cells resistant to first-line immunotherapeutics.

    Call: OPUS 18 , Panel: NZ6

    Principal investigator: dr hab. Marcin Okrój

    Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  10. Identifying and overcoming mechanisms promoting resistance to venetoclax in B cell acute lymphoblastic leukemia with MLL...

    Call: PRELUDIUM 16 , Panel: NZ5

    Principal investigator: dr Klaudyna Fidyt

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  11. The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in...

    Call: PRELUDIUM 16 , Panel: NZ5

    Principal investigator: Sonia Trojan

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Lekarski

  12. Association of TXNDC5 and calreticulin with decreased ER stress, allowing resistant multiple myeloma cells to by-pass pr...

    Call: PRELUDIUM 15 , Panel: NZ5

    Principal investigator: Tadeusz Kubicki

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Lekarski

  13. Regulation of epithelial to mesenchymal transition and therapy resistance to antitumor therapies by MCPIP1

    Call: SONATA BIS 7 , Panel: NZ5

    Principal investigator: dr hab. Katarzyna Miękus

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  14. Proteomic analysis of myeloma plasma cells to determine proteins and pathways involved in acquired resistance to proteas...

    Call: OPUS 13 , Panel: NZ5

    Principal investigator: dr hab. Dominik Dytfeld

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Lekarski

  15. Zinc Deficiency: An essential Variable for the Induction od Resistance to Antidepressants

    Call: PRELUDIUM 13 , Panel: NZ5

    Principal investigator: dr Anna Rafało-Ulińska

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  16. Evaluation of anticancer potential of glutamine metabolism modulation in multiple myeloma sensitive and resistant to che...

    Call: PRELUDIUM 11 , Panel: NZ5

    Principal investigator: Monika Prełowska

    Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego

  17. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Bielecka

    Wojskowy Instytut Medyczny